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EDITORIAL / Technical
Renal  artery  denervation  for  the  treatment
of resistant  hypertension.  Update  after
Medtronic announcement  that  its
Symplicity HTN3  study  failed  to  meet  its
primary efﬁcacy  end  pointCatheter-based  renal  denervation  consists  of  delivering  radiofrequency  (RF)  energy  or
ultrasound  to  interrupt  afferent  and  efferent  sympathetic  nerve  ﬁbres  which  run  through
the  renal  artery  adventitia  which,  together  with  other  systems,  contribute  to  regulating
arterial  blood  pressure.The results  of  the  ﬁrst  Symplicity  HTN2  study  using  a  unipolar  RF  catheter  in  a  random-
ized  trial  of  106  patients  with  resistant  arterial  hypertension  (AHT)  were  published  in  the
Lancet  in  2010  and  were  hailed  enthusiastically  by  both  medical  community  and  patients,
an  enthusiasm  nourished  by  the  manufacturer’s  claim  that  ‘‘the  treatment’’  for  resistant
AHT  had  at  last  been  discovered.  Instrumental  treatment  of  AHT  was  born  and  with  it,
seemingly  limitless  possibilities  for  ﬁnancial  gain.  Although  the  procedure  is  founded  on
several  years’  experience  with  the  method  and  earlier  data  obtained  with  surgical  sym-
pathectomy,  some  clinical  research  groups  had  already  dealt  a  tempering  blow  to  this
enthusiasm  by  pointing  out  the  methodological  weaknesses  of  the  Symplicity  HTN2  study
which  was  carried  out  under  open  conditions.  They  therefore  asked  for  other,  controlled
trials  involving  a  larger  patient  population  to  be  carried  out  without  the  direct  involve-
ment  of  industry  since,  as  several  decades  of  research  into  its  pathophysiology  clearly  show,
blood  pressure  regulation  is  a complex  issue  and  AHT  has  a  gradual,  encroaching  course.
This  came  too  late  to  stop  the  ensuing  frenzy,  with  dozens  of  manufacturers  inundating
the  market,  the  procedure  being  reimbursed  in  certain  European  countries,  thousands  of
procedures  performed  worldwide  with  a variety  of  different  catheters,  and  symposia  and
conferences  devoted  to  the  technique.  Even  the  general  press  got  hold  of  the  subject,
despite  the  fact  that  the  safety  and  efﬁcacy  of  denervation  had  yet  to  be  proved.
http://dx.doi.org/10.1016/j.diii.2014.02.022
2211-5684/© 2014 Published by Elsevier Masson SAS on behalf of the Éditions françaises de radiologie.
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he thunderbolt
n  9  January  2014,  the  medical  community  was  submerged
nder a  wave  of  scepticism  when,  as  is  required  by  Amer-
can legislation  on  stocks  and  markets  under  the  authority
f the  US  Securities  and  Exchange  Commission,  Medtronic
nnounced to  its  ﬁnancial  backers  that  its  US  study,  Symplic-
ty HTN  3,  in  which  570  patients  were  randomised  to  undergo
ither denervation  or  a  ‘‘sham’’  procedure,  had  failed  to
each its  primary  efﬁcacy  endpoint  based  on  a  statistical
ifference of  reduction  in  ofﬁce  blood  pressure  at  6  months
etween the  two  groups.  The  study  did,  however,  achieve  its
rimary safety  endpoint.  Medtronic’s  short  and  to  the  point
ress release  does  not  provide  any  scientiﬁc  results  of  the
tudy which  is  to  be  presented  at  the  ACC  conference  end
r March  2014.  It  also  states  that  three  ongoing  studies  have
een interrupted  for  the  time  being  but  that  the  company
ill continue  to  pursue  its  activities  in  this  sector.  As  no  sci-
ntiﬁc ﬁndings  that  can  be  analysed  by  the  scientiﬁc  and
edical community  have  been  released,  the  scientiﬁc  soci-
ties have,  as  yet,  reserved  judgement.  Nonetheless  and
enerally speaking,  the  initial  hype  has  been  replaced  by
omplete mistrust  in  the  minds  of  many  doctors  and  man-
facturers alike.  Some  manufacturers  have  even  called  a
alt to  their  development  programs.  This  includes  Covidien
lthough the  company  had  been  poised  to  launch  its  own
arge, controlled  trial,  the  reasons  given  being  the  size  of
he market  and  its  prospects  for  growth  and  delays  likely  to
e related  to  ﬁnancial  returns  on  investment.  As  doctors,  it
s our  duty  to  keep  our  heads  and  stay  focussed.  Individual
xperiences and  non-randomised  studies  conducted  around
he world  tend  to  indicate  that  denervation  does  indeed
ork for  certain  patients.  The  scientiﬁc  question  therefore
emains: who  is  a  suitable  candidate  for  this  technique,Editorial
he  short-term  safety  of  which  appears  to  be  satisfactory,
lthough sporadic  cases  of  de  novo  renal  artery  stenosis
r exacerbation  of  existing  stenosis  are  more  commonly
eported? For  the  moment,  attempts  to  identify  potential
arkers of  efﬁcacy  before  renal  denervation  and  thus  deﬁne
he ad  hoc  patient  population  have  been  unsuccessful.  The
esults of  the  French  multi-centre  study  (DenerHTN),  the
econd major  study  conducted  in  this  ﬁeld,  will  be  available
n June  2014.
Pending these  results  and  the  publication  of  the  ofﬁ-
ial Symplicity  HTN3  results,  we  must  remain  calm  and
ontinue to  study  these  techniques  patiently  and  method-
cally.
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